GH therapy and cancer risk in hypopituitarism: What we know from human studies

European Journal of Endocrinology

Volumn 169, Issue 5, 2013, Pages

  Pekic, Sandra ^a   Popovic, Vera ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GROWTH HORMONE; HYPOPHYSIS HORMONE; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 4; SOMATOMEDIN BINDING PROTEIN 6; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

ACROMEGALY; BREAST CANCER; CANCER GROWTH; CANCER INCIDENCE; CANCER MORTALITY; CANCER RESISTANCE; CANCER RISK; CARCINOGENESIS; COLORECTAL CANCER; CONGENITAL DISORDER; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; ENVIRONMENTAL FACTOR; GENE; GENE MUTATION; GHRH GENE; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; HEALTH BEHAVIOR; HIGH RISK PATIENT; HORMONE BLOOD LEVEL; HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; HYPOPITUITARISM; INSULIN RESISTANCE; IRRADIATION; LEUKEMIA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; METASTASIS POTENTIAL; NONHUMAN; OBSERVATIONAL STUDY; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROSTATE CANCER; REFERENCE VALUE; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK MANAGEMENT; RISK REDUCTION; SECOND CANCER; SOMATOMEDIN C BLOOD LEVEL; SOMATOMEDIN C DEFICIENCY;

ACROMEGALY; ADULT; CHILD; HUMAN GROWTH HORMONE; HUMANS; HYPOPITUITARISM; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR I; NEOPLASMS; OBESITY; PITUITARY NEOPLASMS; RECOMBINANT PROTEINS; RISK; RISK FACTORS; SOMATOMEDINS;

EID: 84885101641     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-13-0389     Document Type: Review

References (83)

1. Moon HD, Simpson ME, Li CH & Evans HM. Neoplasms in rats treated with pituitary growth hormone; pulmonary and lymphatic tissues. Cancer Research 1950 10 297-308.
2. Young S. Induction of mammary carcinoma in hypophysecto-mized rats treated with 3-methylcholanthrene, oestradiol-17p, progesterone and growth hormone. Nature 1961 190 356-357. (doi:10.1038/190356a0)
3. Harada Y. Pituitary role in the growth of metastasizing MRMT-1 mammary carcinoma in rats. Cancer Research 1976 36 18-22.
4. Rose DP & Noonan JJ. Influence of prolactin and growth hormone on rat mammary tumors induced by N-nitrosomethylurea. Cancer Research 1982 42 35-38.
5. Samani AA, Yakar S, LeRoith D & Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocrine Reviews 2007 28 20-47. (doi:10.1210/er.2006-0001)
6. Seccareccia E & Brodt P. The role of the insulin-like growth factor-I receptor in malignancy: an update. Growth Hormone & IGF Research 2012 22 193-199. (doi:10.1016/j.ghir.2012.09.003)
7. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM & Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004 363 1346-1353. (doi:10.1016/S0140-6736 (04) 16044-3)
8. Pollak MN, Schernhammer ES & Hankinson SE. Insulin-like growth factors and neoplasia. Nature Reviews. Cancer 2004 4 505-518. (doi:10.1038/nrc1387)
9. Swerdlow AJ, Higgins CD, Adlard P & Preece MA. Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-85: a cohort study. Lancet 2002 360 273-277. (doi:10.1016/S0140-6736 (02) 09519-3)
10. Monson JP. Long-term experience with GH replacement therapy: efficacy and safety. European Journal of Endocrinology 2003 148 (Suppl 2) S9-S14. (doi:10.1530/eje.0.148S009)
11. Svensson J, Bengtsson B-A, Rosen T, Oden A & Johannsson G. Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy. Journal of Clinical Endocrinology and Metabolism 2004 89 3306-3312. (doi:10.1210/jc.2003-031601)
12. Abs R, Bengtsson B-A, Hernberg-Stahl E, Monson JP, Tauber JP, Wilton P & Wiister C. GH replacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety. Clinical Endocrinology 1999 50 703-713. (doi:10.1046/j.1365-2265.1999.00695.x)
13. Murray RD, Darzy KH, Gleeson HK & Shalet SM. GH-deficient survivors of childhood cancer: GH replacement during adult life. Journal of Clinical Endocrinology and Metabolism 2002 87 129-135. (doi:10.1210/jc.87.1.129)
14. Wilton P, Mattsson AF & Darendeliler F. Growth hormone treatment in children is not associated with an increase in the incidence of cancer: experience from KIGS (Pfizer International Growth Database). Journal of Pediatrics 2010 157 265-270. (doi:10.1016/j.jpeds.2010.02.028)
15. Bell J, Parker KL, Swinford RD, Hoffman AR, Maneatis T & Lippe B. Long-term safety of recombinant human growth hormone in children. Journal of Clinical Endocrinology and Metabolism 2010 95 167-177. (doi:10.1210/jc.2009- 0178)
16. Sklar CA, Mertens AC, Mitby P, Occhiogrosso G, Qin J, Heller G, Yasui Y & Robison LL. Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the childhood cancer survivor study. Journal of Clinical Endocrinology and Metabolism 2002 87 3136-3141. (doi:10.1210/jc.87.7.3136)
17. Ergun-Longmire B, Mertens AC, Mitby P, Qin J, Heller G, Shi W, Yasui Y, Robison LL & Sklar CA. Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. Journal of Clinical Endocrinology and Metabolism 2006 91 3494-3498. (doi:10.1210/jc.2006-0656)
18. Holly J M P & Perks CM. Insulin-like growth factor physiology. Endocrinology and Metabolism Clinics of North America 2012 41 249-263. (doi:10.1016/j.ecl.2012.04.009)
19. Maile LA & Holly JM. Insulin-like growth factor binding protein (IGFBP) proteolysis: occurrence, identification, role and regulation. Growth Hormone & IGF Research 1999 9 85-95. (doi:10.1054/ghir. 1999.0096)
20. Bartke A & Brown-Borg H. Life extension in the dwarf mouse. Current Topics in Developmental Biology 2004 63 189-225. (doi:10.1016/S0070-2153 (04) 63006-7)
21. Ikeno Y, Hubbard GB, Lee S, Cortez LA, Lew CM, Webb CR, Berryman DE, List EO, Kopchick JJ & Bartke A. Reduced incidence and delayed occurrence of fatal neoplastic diseases in growth hormone receptor/binding protein knockout mice. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences 2009 64 522-529. (doi:10.1093/gerona/glp017)
22. Yang XF, Bearmer WG, Huynh H & Pollak M. Reduced growth of human breast cancer xenografts in hosts homozygous for the lit mutation. Cancer Research 1996 56 1509-1511.
23. Wu Y, Yakar S, Zhao L, Hennighausen L & LeRoith D. Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Research 2002 62 1030-1035.
24. Wu Y, Cui K, Miyoshi K, Hennighausen L, Green JE, Setser J, LeRoith D & Yakar S. Reduced circulating insulin-like growth factor I levels delay the onset ofchemically and genetically induced mammary tumors. Cancer Research 2003 63 4384-4388.
25. Ohneda K, Ulshen MH, Fuller CR, D'Ercole AJ & Lund PK. Enhanced growth of small bowel in transgenic mice expressing human insulin-like growth factor I. Gastroenterology 1997 112 444-454. (doi:10.1053/gast.1997.v112. pm9024298)
26. Freier S, Weiss O, Eran M, Flyvbjerg A, Dahan R, Nephesh I, Safra T, Shiloni E & Raz I. Expression of the insulin-like growth factors and their receptors in adenocarcinoma of the colon. Gut 1999 44 704-708. (doi:10.1136/gut.44.5.704)
27. Khandwala H, McCutcheon I, Flyvberg A & Friend K. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocrine Reviews 2000 21 215-244. (doi:10.1210/er.21.3.215)
28. Holly J & Perks C. Growth hormone and cancer: are we asking the right questions? Clinical Endocrinology 2006 64 122-124. (doi:10.1111/j.1365-2265. 2006.02409.x)
29. Peyrat JP, Bonneterre J, Hecquet B, Vennin P, Louchez MM, Fournier C, Lefebvre J & Demaille A. Plasma insulin-like growth factor-I (IGF-I) concentrations in human breast cancer. European Journal of Cancer 1993 29 A 492-497. (doi:10.1016/S0959-8049 (05) 80137-6)
30. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH & Pollak M. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998 279 563-566. (doi:10.1126/ science.279.5350.563)
31. Hankinson S, Willett W, Colditz G, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE & Pollak M. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998 351 1393-1396. (doi:10.1016/S0140-6736 (97) 10384-1)
32. Ma J, Pollak M, Giovannucci E, Chan JM, Tao Y & Hennekens CH. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. Journal of the National Cancer Institute 1999 91 620-625. (doi:10.1093/jnci/91.7.620)
33. Giovannucci E, Pollak MN, Platz EA, Willett WC, Stampfer MJ, Majeed N, Colditz GA, Speizer FE & Hankinson SE. A prospective study of plasma insulin-like growth factor-I and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiology, Biomarkers & Prevention 2000 9 345-349.
34. Chan J, Stampfer M, Giovannucci E, Ma J & Pollak M. Insulin-like growth factor I (IGF-I), IGF binding protein-3 and prostate cancer risk: epidemiological studies. Growth Hormone & IGF Research 2000 10 (Suppl A) S32-S33. (doi:10.1016/S1096-6374 (00) 90015-7)
35. Shaneyfelt T, Husein R, Bubley G & Mantzoros C. Hormonal predictors of prostate cancer: a meta-analysis. Journal of Clinical Oncology 2000 18 847-853.
36. Rowlands MA, Holly JM, Gunnell D, Donovan J, Lane JA, Hamdy F, Neal DE, Oliver S, Smith GD & Martin RM. Circulating insulin-like growth factors and IGF-binding proteins in PSA-detected prostate cancer: the large case-control study ProtecT. Cancer Research 2012 72 503-515. (doi:10.1158/0008-5472. CAN-11-1601)
37. Stattin P, Bylund A, Rinaldi S, Biessy C, Dechaud H, Stenman UH, Egevad L, Riboli E, Hallmans G & Kaaks R. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. Journal of the National Cancer Institute 2000 92 1910-1917. (doi:10.1093/jnci/92.23.1910)
38. Chokkalingam AP, Pollak M, Fillmore CM, Gao YT, Stanczyk FZ, Deng J, Sesterhenn IA, Mostofi FK, Fears TR, Madigan MP et al. Insulin-like growth factors and prostate cancer: a population-based case-control study in China. Cancer Epidemiology, Biomarkers & Prevention 2001 10 421-427.
39. Pazaitou-Panayiotou K, Kelesidis T, Kelesidis I, Kaprara A, Blakeman J, Vainas I, Mpousoulegas A, Williams CJ & Mantzoros C. Growth hormone-binding protein is directly and IGFBP-3 is inversely associated with risk of female breast cancer. European Journal of Endocrinology 2007 156 187-194. (doi:10.1530/EJE-06-0611)
40. Baglietto L, English DR, Hopper JL, Morris HA, Tilley WD & Giles GG. Circulating insulin-like growth factor-I and binding protein-3 and the risk of breast cancer. Cancer Epidemiology, Biomarkers & Prevention 2007 16 763-768. (doi:10.1158/1055-9965. EPI-06-0960)
41. Rinaldi S, Cleveland R, Norat T, Biessy C, Rohrmann S, Linseisen J, Boeing H, Pischon T, Panico S, Agnoli C et al. Serum levels of IGF-I, IGFBP-3 and colorectal cancer risk: results from the EPIC cohort, plus a meta-analysis of prospective studies. International Journal of Cancer 2010 126 1702-1715. (doi:10.1002/ijc.24927)
42. Burgers AM, Biermasz NR, Schoones JW, Pereira AM, Renehan AG, Zwahlen M, Egger M & Dekkers OM. Meta-analysis and dose-response metaregression: circulating insulin-like growth factor I (IGF-I) and mortality. Journal of Clinical Endocrinology and Metabolism 2011 96 2912-2920. (doi:10.1210/jc.2011- 1377)
43. Svensson J, Carlzon D, Petzold M, Karlsson MK, Ljunggren O, Tivesten A, Mellstrom D & Ohlsson C. Both low and high serum IGF-I levels associate with cancer mortality in older men. Journal of Clinical Endocrinology and Metabolism 2012 97 4623-4630. (doi:10.1210/jc.2012-2329)
44. Rosen T & Bengtsson B-A. Premature mortality due to cardiovascular diseases in hypopituitarism. Lancet 1990 336 285-288. (doi:10.1016/0140-6736 (90) 91812-0)
45. Stochholm K, Gravholt C, Laursen T, Laurberg P, Andersen M, Kristensen LO, Feldt-Rasmussen U, Christiansen JS, Frydenberg M & Green A. Mortality and GH deficiency: a nationwide study. European Journal of Endocrinology 2007 157 9-18. (doi:10.1530/EJE-07-0013)
46. Bates A, Van't Hoff W, Jones P & Clayton R. The effect of hypopituitarism on life expectancy. Journal of Clinical Endocrinology and Metabolism 1996 81 1169-1172. (doi: 10.1210/jc.81.3.1169)
47. Popovic V, Damjanovic S, Micic D, Nesovic M, Djurovic M, Petakov M, Obradovic S, Zoric S, Simic M, Penezic Z et al. Increased incidence of neoplasia in patients with pituitary adenoma. The Pituitary Study Group. Clinical Endocrinology 1998 49 441-445. (doi:10.1046/j.1365-2265.1998.00536.x)
48. Tomlinson J, Holden N, Hills R, Wheatley K, Clayton RN, Bates AS, Sheppard MC & Stewart PM. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypo-pituitary Study Group. Lancet 2001 357 425-431. (doi:10.1016/S0140-6736 (00) 04006-X)
49. Erfurth EM, Bullow B, Mikoczy Z & Hagmar L. Incidence of a second tumor in hypopituitary patients operated for pituitary tumors. Journal of Clinical Endocrinology and Metabolism 2001 86 659-662. (doi:10.1210/jc.86.2.659)
50. Bulow B, Hagmar L, Mikoczy Z, Nordstrom CH & Erfurth EM. Increased cerebrovascular mortality in patients with hypopituitarism. Clinical Endocrinology 1997 46 75-81. (doi:10.1046/j.1365-2265.1997.d01-1749.x)
51. Krzisnik C, Grguric S, Cvijovic K & Laron Z. Longevity of the hypopituitary patients from the island Krk: a follow-up study. Pediatric Endocrinology Reviews 2010 7 357-362.
52. Besson A, Salemi S, Gallati S, Jenal A, Horn R, Mullis PS & Mullis PE. Reduced longevity in untreated patients with isolated growth hormone deficiency. Journal of Clinical Endocrinology and Metabolism 2003 88 3664-3667. (doi:10.1210/jc.2002-021938)
53. Aguiar-Oliveira MH, Oliveira FT, Pereira RM, Oliveira CR, Blackford A, Valenca EH, Santos EG, Gois-Junior MB, Meneguz-Moreno RA, Araujo VP et al. Longevity in untreated congenital growth hormone deficiency due to a homozygous mutation in the GHRH receptor gene. Journal of Clinical Endocrinology and Metabolism 2010 95 714-721. (doi:10.1210/jc.2009-1879)
54. Shevah O & Laron Z. Patients with congenital deficiency of IGF-I seem protected from the development of malignancies: a preliminary report. Growth Hormone & IGF Research 2007 17 54-57. (doi:10.1016/j.ghir.2006.10.007)
55. Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, Wei M, Madia F, Cheng CW, Hwang D, Martin-Montalvo A, Saavedra J, Ingles S et al. Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Science Translational Medicine 2011 3 70ra13. (doi:10.112 6/scitranslmed.3001845)
56. Rosenfeld RG, Cohen P, Robison LL, Bercu BB, Clayton P, Hoffman AR, Radovick S, Saenger P Savage MO & Wit JM. Long-term surveillance of growth hormone therapy. Journal of Clinical Endocrinology and Metabolism 2012 97 68-72. (doi:10.1210/jc.2011-2294)
57. Gutierrez LP, Koltowska-Haggström M, Jonsson PJ, Mattsson AF, Svensson D, Westberg B & Luger A. Registries as a tool in evidence-based medicine: example of KIMS (Pfizer International Metabolic Database). Pharmacoepidemiology and Drug Safety 2008 17 90-102. (doi:10.1002/pds.1510)
58. de Boer H, Blok GJ & Van der Veen EA. Clinical aspects of growth hormone deficiency in adults. Endocrine Reviews 1995 16 63-86. (doi:10.1210/er. 16.1.63)
59. van Bunderen CC, van Nieuwpoort IC, Arwert LI, Heymans MW, Franken AA, Koppeschaar HP, van der Lely AJ & Drent ML. Does growth hormone replacement therapy reduce mortality in adults with growth hormone deficiency? Data from the Dutch National Registry of Growth Hormone Treatment in adults. Journal of Clinical Endocrinology and Metabolism 2011 96 3151-3159. (doi:10.1210/jc.2011- 1215)
60. Gaillard RC, Mattsson AF, Akerblad AC, Bengtsson BA, Cara J, Feldt-Rasmussen U, Koltowska-Haggström M, Monson JP, Saller B, Wilton P et al. Overall and cause-specific mortality in GH-deficient adults on GH replacement. European Journal of Endocrinology 2012 166 1069-1077. (doi:10.1530/EJE-11-1028)
61. KIMS (Pfizer International Metabolic Database). "Safety, ". In Overview, vol 13, pp 27-30. Eds P Touraine & M Koltowska-Haggstrom, 2010.
62. Burman P, Mattsson AF, Johannsson G, Hoybye C, Holmer H, Dahlqvist P, Berinder K, Engstrom BE, Ekman D, Erfurth EM et al. Deaths among adult patients with hypopituitarism: hypocortisolism during acute stress, and de novo malignant brain tumors contribute to an increased mortality. Journal of Clinical Endocrinology and Metabolism 2013 98 1466-1475. (doi:10.1210/jc.2012-4059)
63. Popovic V, Mattsson AF, Gaillard RC, Wilton P, Koltowska-Haggstrom M & Ranke MB. Serum insulin-like growth factor I (IGF-I), IGF-binding proteins 2 and 3, and the risk for development of malignancies in adults with growth hormone (GH) deficiency treated with GH: data from KIMS (Pfizer International Metabolic Database). Journal of Clinical Endocrinology and Metabolism 2010 95 4449-4454. (doi:10.1210/jc.2010-0287)
64. Child CJ, Zimmermann AG, Woodmansee WW, Green DM, Li JJ, Jung H, Erfurth EM, Robison LL & HypoCCS International Advisory Board. Assessment of primary cancers in GH-treated adult hypopituitary patients: an analysis from the Hypopituitary Control and Complications Study. European Journal of Endocrinology 2011 165 217-223. (doi:10.1530/EJE-11-0286)
65. Hartman ML, Xu R, Crowe BJ, Robison LL, Erfurth EM, Kleinberg DL, Zimmermann AG, Woodmansee WW, Cutler GB Jr, Chipman JJ et al. Prospective safety surveillance of GH-deficient adults: comparison of GH-treated vs untreated patients. Journal of Clinical Endocrinology and Metabolism 2013 98 980-988. (doi:10.1210/jc.2012-2684)
66. Holdaway IM, Rajasoorya RC & Gamble GD. Factors influencing mortality in acromegaly. Journal of Clinical Endocrinology and Metabolism 2004 89 667-674. (doi:10.1210/jc.2003-031199)
67. Ben-Shlomo A, Sheppard MC, Stephens JM, Pulgar S & Melmed S. Clinical, quality of life, and economic value of acromegaly disease control. Pituitary 2011 14 284-294. (doi:10.1007/s11102-011-0310-7)
68. Orme SM, McNally RJ, Cartwright RA & Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. Journal of Clinical Endocrinology and Metabolism 1998 83 2730-2734. (doi:10.1210/jc.83.8.2730)
69. Bengtsson B-A. Acromegaly and neoplasia. Journal of Pediatric Endocrinology 1993 6 73-78. (doi:10.1515/JPEM.1993.6.1.73)
70. Jenkins P & Besser M. Clinical perspective: acromegaly and cancer: a problem. Journal of Clinical Endocrinology and Metabolism 2001 86 2935-2941. (doi:10.1210/jc.86.7.2935)
71. Renehan AG, Odwyer ST & Shalet SM. Screening colonoscopy for acromegaly in perspective. Clinical Endocrinology 2001 55 731-733. (doi:10.1046/j.1365-2265.2001.01355.x)
72. Bhansali A, Kochhar R, Chawla YK, Reddy S & Dash RJ. Prevalence of colonic polyps is not increased in patients with acromegaly: analysis of 60 patients from India. Journal of Gastroenterology and Hepatology 2004 19 266-269. (doi:10. 1111/j.1440-1746.2003.03282.x)
73. Gullu BE, Celik O, Gazioglu N & Kadioglu P. Thyroid cancer is the most common cancer associated with acromegaly. Pituitary 2010 13 242-248. (doi:10.1007/s11102-010-0224-9)
74. Dutta P, Bhansali A, Vaiphei K, Dutta U, Ravi Kumar P, Masoodi S, Mukherjee KK, Varma A & Kochhar R. Colonic neoplasia in acromegaly: increased proliferation or deceased apoptosis? Pituitary 2012 15 166-173. (doi:10.1007/s11102-011-0300-9)
75. Renehan AG, O'Connell J, O'Halloran D, Shanahan F, Potten CS, O'Dwyer ST & Shalet SM. Acromegaly and colorectal cancer: a comprehensive review of epidemiology, biological mechanisms, and clinical implications. Hormone and Metabolic Research 2003 35 712-725. (doi:10.1055/s-2004-814150)
76. Loeper S & Ezzat S. Acromegaly: re-thinking the cancer risk. Reviews in Endocrine and Metabolic Disorders 2008 9 41-58. (doi:10.1007/s11154-007-9063- z)
77. Hemminki K, Forsti A & Ji J. Incidence and familial risks in pituitary adenoma and associated tumors. Endocrine-Related Cancer 2007 14 103-109. (doi:10.1677/ERC-06-0008)
78. Koppelman V Schagen SB, Poels MM, Boogerd W, Seynaeve C, van der Luqt A & Breteler MM. Incidental findings on brain magnetic resonance imaging in long-term survivors of breast cancer treated with adjuvant chemotherapy. European Journal of Cancer 2011 47 2531-2536. (doi:10.1016/j.ejca.2011.06.026)
79. Forte V, Pandey A, Abdelmessih R, Forte G, Whaley-Connell A, Sowers JR & McFarlane SI. Obesity, diabetes, the cardiorenal syndrome, and risk for cancer. Cardiorenal Medicine 2012 2 143-162. (doi:10.1159/000337314)
80. Calle EE, Rodriguez C, Walker-Thurmond K & Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U. S. adults. New England Journal of Medicine 2003 348 1625-1638. (doi:10.1056/ NEJMoa021423)
81. Bardou M, Barkun AN & Martel M. Obesity and colorectal cancer. Gut 2013 62 933-947. (doi:10.1136/gutjnl-2013-304701)
82. Garg SK, Maurer H, Reed K & Selaqamsetty R. Diabetes and cancer: two diseases with obesity as a common risk factor. Diabetes, Obesity & Metabolism 2013. In press. (doi:10.1111/dom.12124)
83. DuSell CD & McDonnell DP. 27-Hydroxycholesterol: a potential endogenous regulator of estrogen receptor signaling. Trends in Pharmacological Sciences 2008 29 510-514. (doi:10.1016/j.tips.2008.07.003)